RTI Surgical (RTIX) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 04, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	RTIX
Entity Registrant Name	RTI SURGICAL, INC.
Entity Central Index Key	1,100,441
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		59,509,094

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 13,675	$ 13,849
Accounts receivable-less allowances of $1,787 at June 30, 2017 and $1,728 at December 31, 2016	39,099	41,488
Inventories-net	116,773	119,743
Prepaid and other current assets	6,177	5,213
Assets held for sale	1,750
Total current assets	177,474	180,293
Property, plant and equipment-net	84,379	83,298
Deferred tax assets-net	24,868	24,968
Goodwill	54,887	54,887
Other intangible assets-net	23,995	23,994
Other assets-net	991	591
Total assets	366,594	368,031
Current Liabilities:
Accounts payable	27,745	26,112
Accrued expenses	20,950	22,030
Current portion of deferred revenue	4,718	4,742
Current portion of short and long-term obligations	5,779	6,080
Total current liabilities	59,192	58,964
Long-term obligations-less current portion	74,360	77,267
Other long-term liabilities	841	256
Deferred revenue	6,176	6,612
Total liabilities	140,569	143,099
Preferred stock Series A, $.001 par value: 5,000,000 shares authorized; 50,000 shares issued and outstanding	61,941	60,016
Stockholders' equity:
Common stock, $.001 par value: 150,000,000 shares authorized; 59,445,223 and 58,433,397 shares issued and outstanding, respectively	59	58
Additional paid-in capital	418,884	417,428
Accumulated other comprehensive loss	(6,903)	(8,316)
Accumulated deficit	(246,899)	(243,338)
Less treasury stock, 410,396 and 368,949 shares, respectively, at cost	(1,057)	(916)
Total stockholders' equity	164,084	164,916
Total liabilities and stockholders' equity	$ 366,594	$ 368,031

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 1,787	$ 1,728
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	59,445,223	59,445,223
Common stock, shares outstanding	58,433,397	58,433,397
Treasury stock, shares	410,396	368,949

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues	$ 72,120	$ 67,620	$ 142,059	$ 134,971
Costs of processing and distribution	35,157	33,671	69,317	64,997
Gross profit	36,963	33,949	72,742	69,974
Expenses:
Marketing, general and administrative	29,496	28,402	59,167	55,954
Research and development	3,740	4,084	7,428	8,245
Severance charges	3,400	711	7,803	711
Restructuring charges		1,107		1,107
Contested proxy expenses		2,372		2,680
Total operating expenses	36,636	36,676	74,398	68,697
Operating income (loss)	327	(2,727)	(1,656)	1,277
Other (expense) income:
Interest expense	(915)	(392)	(1,734)	(753)
Interest income		6		7
Foreign exchange (loss) gain	(75)	(38)	(55)	8
Total other expense-net	(990)	(424)	(1,789)	(738)
(Loss) income before income tax (provision) benefit	(663)	(3,151)	(3,445)	539
Income tax (provision) benefit	(1,026)	859	(116)	(430)
Net (loss) income	(1,689)	(2,292)	(3,561)	109
Convertible preferred dividend	(924)	(870)	(1,834)	(1,728)
Net loss applicable to common shares	(2,613)	(3,162)	(5,395)	(1,619)
Other comprehensive loss:
Unrealized foreign currency translation gain (loss)	1,093	(556)	1,413	(94)
Comprehensive loss	$ (1,520)	$ (3,718)	$ (3,982)	$ (1,713)
Net loss per common share-basic	$ (0.04)	$ (0.05)	$ (0.09)	$ (0.03)
Net loss per common share-diluted	$ (0.04)	$ (0.05)	$ (0.09)	$ (0.03)
Weighted average shares outstanding-basic	58,935,786	58,215,477	58,715,791	58,065,185
Weighted average shares outstanding-diluted	58,935,786	58,215,477	58,715,791	58,065,185

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Series A Preferred Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2016	$ 164,916		$ 58	$ 417,428		$ (8,316)	$ (243,338)	$ (916)
Net loss	(3,561)						(3,561)
Foreign currency translation adjustment	1,413					1,413
Exercise of common stock options	1,575		1	1,574
Stock-based compensation	1,808			1,808
Purchase of treasury stock	(141)							(141)
Amortization of preferred stock Series A issuance costs		$ (92)			$ (92)
Preferred stock Series A dividend		$ (1,834)			$ (1,834)
Ending Balance at Jun. 30, 2017	$ 164,084		$ 59	$ 418,884		$ (6,903)	$ (246,899)	$ (1,057)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net (loss) income	$ (1,689)	$ (2,292)	$ (3,561)	$ 109
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization expense	3,561	4,384	7,129	8,694
Provision for bad debts and product returns	216	191	560	495
Provision for inventory write-downs	1,964	1,425	3,753	2,370
Amortization of deferred revenue	(1,186)	(1,217)	(2,460)	(2,434)
Deferred income tax provision (benefit)	524	(532)	(561)	(119)
Stock-based compensation	974	600	1,808	1,100
Other	759	96	873	264
Change in assets and liabilities:
Accounts receivable	(2,777)	4,467	2,128	9,540
Inventories	(567)	(241)	167	(4,572)
Accounts payable	890	1,731	998	4,495
Accrued expenses	(1,963)	(1,242)	(1,384)	(8,318)
Deferred revenue			2,000	2,000
Other operating assets and liabilities	330	(584)	(837)	(415)
Net cash provided by operating activities	1,036	6,786	10,613	13,209
Cash flows from investing activities:
Purchases of property, plant and equipment	(3,877)	(4,766)	(7,160)	(9,403)
Patent and acquired intangible asset costs	(1,526)	(195)	(1,845)	(1,391)
Net cash used in investing activities	(5,403)	(4,961)	(9,005)	(10,794)
Cash flows from financing activities:
Proceeds from exercise of common stock options	1,467	14	1,575	14
Proceeds from long-term obligations	2,000	4,000	4,000	7,000
Net payments from short-term obligations		(600)		(849)
Payments on long-term obligations	(3,125)	(4,166)	(7,375)	(8,299)
Other financing activities			(142)	(108)
Net cash provided by (used in) financing activities	342	(752)	(1,942)	(2,242)
Effect of exchange rate changes on cash and cash equivalents	102	(47)	160	(33)
Net (decrease) increase in cash and cash equivalents	(3,923)	1,026	(174)	140
Cash and cash equivalents, beginning of period	17,598	11,728	13,849	12,614
Cash and cash equivalents, end of period	13,675	12,754	13,675	12,754
Supplemental cash flow disclosure:
Cash paid for interest	845	396	2,303	789
Cash paid for income taxes, net of refunds	32	138	32	176
Non-cash acquisition of property, plant and equipment	566	1,128	879	1,257
Increase in accrual for dividend payable	$ 924	$ 870	$ 1,834	$ 1,728

Operations and Organization

Operations and Organization	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operations and Organization	1. Operations and Organization The Company is a leader in the use of natural tissues, metals and synthetics to produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE ® ® ®

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, which the Company considers necessary for a fair presentation of the results of operations for the periods shown. The condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q 10-01 S-X, 10-K The condensed consolidated financial statements include the accounts of RTI Surgical, Inc. and its wholly owned subsidiaries, Pioneer Surgical Technology, Inc. (“Pioneer”), Tutogen Medical, Inc. (“TMI”), RTI Surgical, Inc. – Cardiovascular (inactive), Biological Recovery Group, Inc. (inactive) and RTI Services, Inc. (inactive). The condensed consolidated financial statements also include the accounts of RTI Donor Services, Inc. (“RTIDS”), which is a controlled entity.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Standards	3. Recently Issued Accounting Standards Compensation—Stock Compensation 2017-09, “Compensation—Stock Compensation” Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets 2017-05, “Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets” 610-20): Simplifying the Test for Goodwill Impairment No. 2017-04, Simplifying the Test for Goodwill Impairment” No. 2017-04”). No. 2017-04 No. 2017-04, No. 2017-04 No. 2017-04 Compensation – Stock Compensation No. 2016-09, “Compensation – Stock Compensation” 2016-09”). 2016-09 2016-09 ASU 2016-09 pre-adoption share-based based-payments In addition, under ASU 2016-09 2016-09 Simplifying the Measurement of Inventory No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” No. 2015-11 first-in, first-out No. 2015-11 No. 2015-11 2015-11 2015-11 Revenue from Contracts with Customers No. 2014-09, “Revenue from Contracts with Customers” 2014-09”), “Revenue Recognition” 2014-09 2014-09 2014-09 In March and April 2016, the FASB issued two updates to the revenue recognition guidance: ASU 2016-08 “Principal Versus Agent Considerations” 2016-10, “Identifying Performance Obligations and Licensing” In May 2016, the FASB issued ASU Update No. 2016-12 2016-12”) The Company has not determined the impact ASU 2014-09, 2016-08, 2016-10 2016-12

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	4. Stock-Based Compensation The Company’s policy is to grant stock options at an exercise price equal to 100% of the market value of a share of common stock at closing on the date of the grant. The Company’s stock options generally have ten-year over a one to five-year period from the date of grant. The Company’s policy is to grant restricted stock awards at a fair value equal to 100% of the market value of a share of common stock at closing on the date of the grant. The Company’s restricted stock awards generally vest over one to three-year periods. 2015 Incentive Compensation Plan – Stock Options As of June 30, 2017, there was $2,140 of total unrecognized stock-based compensation related to nonvested stock options. The expense related to these stock options is expected to be recognized over a weighted-average period of 3.39 years. Stock options outstanding, exercisable and available for grant at June 30, 2017, are summarized as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Life (Years) Value Outstanding at January 1, 2017 5,764,607 $ 4.28 Granted 456,038 4.53 Exercised (426,639 ) 3.69 Forfeited or expired (647,661 ) 5.98 Outstanding at June 30, 2017 5,146,345 $ 4.13 5.63 $ 9,383 Vested or expected to vest at June 30, 2017 4,891,474 $ 4.12 5.47 $ 8,992 Exercisable at June 30, 2017 3,771,493 $ 4.07 4.63 $ 7,235 Available for grant at June 30, 2017 5,281,115 The aggregate intrinsic value in the tables above represents the total pre-tax Other information concerning stock options are as follows: For the Six Months Ended June 30, 2017 2016 Weighted average fair value of stock options granted $ 2.24 $ 1.55 Aggregate intrinsic value of stock options exercised 533 6 The aggregate intrinsic value of stock options exercised in a period represents the pre-tax Restricted Stock Awards During the first quarter of 2017, the Company granted 62,500 shares of time-based restricted stock, which vest over a three-year period, with a weighted-average grant date fair value of $3.15 per share and the Company granted 6,331 shares of time-based restricted stock with a weighted-average grant date fair value of $3.70 per share which vest over a one-year one-year For the three and six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation as follows: For the Three Months Ended For the Six Months Ended June 30, June 30, 2017 2016 2017 2016 Stock-based compensation: Costs of processing and distribution $ 22 $ 33 $ 45 $ 66 Marketing, general and administrative 942 552 1,744 1,004 Research and development 10 15 19 30 Total $ 974 $ 600 $ 1,808 $ 1,100 Inducement Grant On January 26, 2017, the Company issued an inducement grant to its President and Chief Executive Officer, Mr. Camille Farhat. This grant was in the form of: (1) a restricted stock award agreement (the “Restricted Stock Agreement #1”); (2) another restricted stock award agreement (the “Restricted Stock Agreement #2”); and (3) a stock option agreement (the “Option Agreement”). Under the Restricted Stock Agreement #1, the Company granted Mr. Farhat 850,000 shares of restricted common stock. On the first anniversary of the Grant Date, 170,000 shares will vest. The remaining shares will vest on the last day of each calendar quarter at a rate of 42,500 shares per calendar quarter commencing after the first anniversary of the Grant Date and continuing for four years after. Vesting of these shares may accelerate upon the occurrence of either of two performance conditions. Under the Restricted Stock Agreement #2, the Company granted Mr. Farhat 150,000 shares of restricted common stock. These 150,000 restricted shares will become fully vested on the latest date (the “Purchase Date”) on which the fair market value of the cumulative amount of shares that Mr. Farhat purchases on the open market equals $500,000, so long as the Purchase Date is on or before March 15, 2018. After vesting, the shares will be non-transferable Under the Option Agreement, the Company granted Mr. Farhat the option to purchase 1,950,000 shares of common stock (the “Stock Options”). The exercise price for the Stock Options is $3.20. The Stock Options will expire on January 26, 2022. The Stock Options will vest based on the Company’s attainment of three average stock price benchmarks. The first 650,000 shares will vest if the Company’s average publicly traded stock price is over $6.00 for a sixty-consecutive calendar day period. The next 650,000 shares will vest if the Company’s average publicly traded stock price is over $7.00 for a sixty-consecutive calendar day period. The final 650,000 shares will vest if the Company’s average publicly traded stock price is over $8.00 for a sixty-consecutive calendar day period. The vesting of the Stock Options is cumulative.

Net Income Per Common Share

Net Income Per Common Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Income Per Common Share	5. Net Income Per Common Share A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net income per common share is presented below: For the Three Months Ended For the Six Months Ended 2017 2016 2017 2016 Basic shares 58,935,786 58,215,477 58,715,791 58,065,185 Effect of dilutive securities: Stock options — — — — Diluted shares 58,935,786 58,215,477 58,715,791 58,065,185 For the three months ended June 30, 2017 and 2016, approximately 1,350,051 and 4,073,600, respectively, and for the six months ended June 30, 2017 and 2016, approximately 2,422,661 and 4,144,433, respectively, of issued stock options were not included in the computation of diluted net income per common share because they were anti-dilutive because their exercise price exceeded the market price. For the three months ended June 30, 2017 and 2016, options to purchase 1,005,138 and 417,311, respectively, and for the six months ended June 30, 2017 and 2016, options to purchase 687,268 and 347,038, respectively, of common stock were not included in the computation of diluted loss per share because dilutive shares are not factored into this calculation when a net loss is reported. For the three and six months ended June 30, 2017 and 2016, 50,000 shares of convertible preferred stock and accrued but unpaid dividends were anti-dilutive on an as if-converted

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories by stage of completion are as follows: June 30, December 31, Unprocessed tissue, raw materials and supplies $ 24,959 $ 31,745 Tissue and work in process 42,420 38,552 Implantable tissue and finished goods 49,394 49,446 $ 116,773 $ 119,743 For the three months ended June 30, 2017 and 2016, the Company had inventory write-downs of $1,964 and $1,425, respectively, and for the six months ended June 30, 2017 and 2016, the Company had inventory write-downs of $3,753 and $2,370, respectively, relating primarily to product obsolescence.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	7. Property, Plant and Equipment Property, plant and equipment are as follows: June 30, December 31, Land $ 2,378 $ 2,324 Buildings and improvements 57,092 59,187 Processing equipment 41,843 38,387 Surgical instruments 21,573 18,394 Office equipment, furniture and fixtures 1,704 1,701 Computer equipment and software 18,931 11,852 Construction in process 11,124 17,554 154,645 149,399 Less accumulated depreciation (70,266 ) (66,101 ) $ 84,379 $ 83,298 For the three months ended June 30, 2017 and 2016, the Company had depreciation expense in connection with property, plant and equipment of $2,652 and $3,454, respectively, and for the six months ended June 30, 2017 and 2016, the Company had depreciation expense in connection with property, plant and equipment of $5,324 and $6,836, respectively. Owned property previously used for administrative, distribution and marketing functions with a cost basis of $1,750 are to be disposed of as a result of improving operational efficiencies were included in “Assets held for sale” on the Condensed Consolidated Balance Sheet as of June 30, 2017, are not included in the table above. On July 21, 2017, the Company entered into a sale agreement with a third party for the owned property. The transaction is expected to close in the fourth quarter 2017.

Other Intangible Assets

Other Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	8. Other Intangible Assets Other intangible assets are as follows: June 30, 2017 December 31, 2016 Gross Accumulated Gross Accumulated Patents $ 11,727 $ 4,565 $ 11,559 $ 4,159 Acquired licensing rights 13,685 8,646 12,204 8,302 Marketing and procurement intangible assets 20,837 9,043 20,694 8,002 Total $ 46,249 $ 22,254 $ 44,457 $ 20,463 Marketing and procurement intangible assets include the following: procurement contracts, trademarks, selling and marketing relationships, customer lists and non-compete For the three months ended June 30, 2017 and 2016, the Company had amortization expense of other intangible assets of $909 and $930, respectively, and for the six months ended June 30, 2017 and 2016, the Company had amortization expense of other intangible assets of $1,805 and $1,858, respectively. At June 30, 2017, management’s estimates of future amortization expense for the next five years are as follows: Amortization 2017 $ 1,700 2018 3,400 2019 3,400 2020 3,400 2021 3,400 2022 3,300 $ 18,600

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2017
Other Liabilities Disclosure [Abstract]
Accrued Expenses	9. Accrued Expenses Accrued expenses are as follows: June 30, December 31, Accrued compensation $ 4,271 $ 4,904 Accrued severance charges 4,494 410 Accrued restructuring charges — 95 Accrued CEO retirement and transition costs 1,096 2,406 Accrued distributor commissions 4,366 4,422 Accrued donor recovery fees 3,376 6,350 Other 3,347 3,443 $ 20,950 $ 22,030 The Company accrues for the estimated donor recovery fees due to third party recovery agencies as tissue is received.

Short and Long-Term Obligations

Short and Long-Term Obligations	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Short and Long-Term Obligations	10. Short and Long-Term Obligations Short and long-term obligations are as follows: June 30, December 31, Term loan $ 47,139 $ 50,347 Credit facility 33,000 33,000 Total 80,139 83,347 Less current portion (5,779 ) (6,080 ) Long-term portion $ 74,360 $ 77,267 The Company obtained from TD Bank and Regions Bank, a 5-year, The total available credit on the Company’s revolving credit facility at June 30, 2017 was $9,500. The Company’s ability to access its revolving credit facility is subject to and can be limited by the Company’s compliance with the Company’s financial and other covenants. The Company was in compliance with the financial covenants related to its revolving credit facility as of June 30, 2017. For the three months ended June 30, 2017 and 2016, interest expense associated with the amortization of debt issuance costs was $150 and $39, respectively, and for the six months ended June 30, 2017 and 2016, interest expense associated with the amortization of debt issuance costs was $262 and $78, respectively. As of June 30, 2017, contractual maturities of long-term obligations are as follows: Term Loan Credit Facility Total 2017 $ 2,873 $ — $ 2,873 2018 44,266 33,000 77,266 $ 47,139 $ 33,000 $ 80,139

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The Company expects its deferred tax assets of $24,868, net of the valuation allowance at June 30, 2017 of $5,899, to be realized through the generation of future taxable income and the reversal of existing taxable temporary differences. Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. As such, valuation allowances of $5,899 and $4,916 have been established at June 30, 2017 and December 31, 2016, respectively, against a portion of the deferred tax assets. U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries. It is not practicable to estimate the amount of tax that might be payable. The Company’s intention is to indefinitely reinvest earnings of its foreign subsidiaries outside of the U.S. The Company evaluates the need for deferred tax asset valuation allowances based on a more likely than not standard. The ability to realize deferred tax assets depends on the ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction. The assessment regarding whether a valuation allowance is required or should be adjusted also considers all available positive and negative evidence. It is difficult to conclude a valuation allowance is not required when there is significant objective and verifiable negative evidence, such as cumulative losses in recent years. The Company utilizes a rolling three years of actual results as the primary measure of cumulative losses in recent years. On a rolling three years, the Company’s U.S. operations are in a cumulative income position. The Company considers this objectively verifiable evidence that its current U.S. operations existing on June 30, 2017, have consistently demonstrated the ability to operate at a profit. The Company has a history of utilizing 100 percent of its U.S. deferred taxes assets before they expire and the forecasts of taxable earnings project a complete realization of all U.S. deferred tax assets before they expire, including under stressed scenarios. The Company’s German and French operations are in three year cumulative loss positions. As a result, the Company has recorded a full valuation allowance on its German and French subsidiaries’ deferred tax assets. The Company will continue to regularly assess the realizability of our deferred tax assets. Changes in historical earnings performance and future earnings projections, among other factors, may cause the Company to adjust its valuation allowance, which would impact the Company’s income tax expense in the period the Company determines that these factors have changed. The Company is undergoing an examination by the Internal Revenue Service (“IRS”). The IRS examination covers the 2015 tax year.

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Preferred Stock	12. Preferred Stock On June 12, 2013, the Company and WSHP Biologics Holdings, LLC, an affiliate of Water Street Healthcare Partners, a leading healthcare-focused private equity firm (“Water Street”), entered into an investment agreement. Pursuant to the terms of the investment agreement, the Company issued $50,000 of convertible preferred equity to Water Street in a private placement which closed on July 16, 2013, with preferred stock issuance costs of $1,290. The preferred stock accrues dividends at a rate of 6% per annum. To the extent dividends are not paid in cash in any quarter, the dividends which have accrued on each outstanding share of preferred stock during such three-month period will accumulate until paid in cash or converted to common stock. Our credit agreement with TD Bank and Regions Bank contains various covenants of financial conditions which, if not met, would restrict the Company from paying dividends. Preferred stock is as follows: Preferred Stock Preferred Stock Net Total Balance at January 1, 2017 $ 60,676 $ (660 ) $ 60,016 Accrued dividend payable 1,834 — 1,834 Amortization of preferred stock issuance costs — 91 91 Balance at June 30, 2017 $ 62,510 $ (569 ) $ 61,941

Severance Charges

Severance Charges	6 Months Ended
	Jun. 30, 2017
Employee Severance [Member]
Severance Charges	13. Severance Charges The Company recorded severance charges to reduce headcount and improve operational efficiencies, which resulted in $7,803 of expenses for the six months ended June 30, 2017. The total severance charges are expected to be paid in full by the first quarter of 2018. Severance payments are made to terminated employees over periods ranging from one month to twelve months and are not expected to have a material impact on cash flows of the Company in any quarterly period. The following table includes a rollforward of severance charges included in accrued expenses, see Note 9. Accrued severance charges at January 1, 2017 $ 410 Employee separation expenses accrued in 2017 7,803 Subtotal severance charges 8,213 Severance cash payments (3,386 ) Stock based compensation (333 ) Accrued severance charges at June 30, 2017 $ 4,494

CEO Retirement and Transition C

CEO Retirement and Transition Costs	6 Months Ended
	Jun. 30, 2017
Postemployment Benefits [Abstract]
CEO Retirement and Transition Costs	14. CEO Retirement and Transition Costs The Company recorded Chief Executive Officer retirement and transition costs related to the retirement of our former Chief Executive Officer pursuant to the Executive Transition Agreement dated August 29, 2012 (as amended and extended to date), which resulted in $4,404 of expenses for the year ended December 31, 2016. The total Chief Executive Officer retirement and transition costs are expected to be paid in full prior to the first quarter of 2019. The following table includes a rollforward of CEO retirement and transition costs included in accrued expenses, see Note 9. Accrued CEO retirement and transition costs at January 1, 2017 $ 2,406 Cash payments (727 ) Other long-term liabilities portion (583 ) Accrued restructuring charges at June 30, 2017 $ 1,096

Legal Actions

Legal Actions	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Legal Actions	15. Legal Actions The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of these claims that were outstanding as of June 30, 2017, will have a material adverse impact on its financial position or results of operations. Coloplast — co-defendant In addition to claims made directly against the Company, Coloplast, a distributor of TSM’s and certain allografts processed and private labeled for them under a contract with the Company, has also been named as a defendant in individual TSM cases in various federal and state courts. Coloplast requested that the Company indemnify or defend Coloplast in those claims which allege injuries caused by the Company’s allograft implants, and on April 24, 2014, Coloplast sued RTI Surgical, Inc. in the Fourth Judicial District of Minnesota for declaratory relief and breach of contract. On December 11, 2014, Coloplast entered into a settlement agreement with RTI Surgical, Inc. and Tutogen Medical, Inc. (the “Company Parties”) resulting in dismissal of the case. Under the terms of the settlement agreement, the Company Parties are responsible for the defense and indemnification of two categories of present and future claims: (1) tissue only (where Coloplast is solely the distributor of Company processed allograft tissue and no Coloplast-manufactured or distributed synthetic mesh is identified) (“Tissue Only Claims”), and (2) tissue plus non-Coloplast (“Tissue-Non-Coloplast Tissue-Non-Coloplast Based on the current information available to the Company, it is not possible to evaluate and estimate with reasonable certainty the impact that current or any future TSM litigation may have on the Company. The Company’s accounting policy is to accrue for legal costs as they are incurred.

Regulatory Actions

Regulatory Actions	6 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
Regulatory Actions	16. Regulatory Actions On September 30, 2014, the Company received a letter from the FDA regarding our map3 ® ® ®

Segment Data

Segment Data	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Data	17. Segment Data The Company distributes human tissue, bovine and porcine animal tissue, metal and synthetic implants through various distribution channels. The Company operates in one reportable segment composed of six lines of business. The reporting of the Company’s lines of business is composed primarily of six categories: spine; sports medicine and orthopedics; surgical specialties; cardiothoracic; international; and global commercial. Discrete financial information is not available for these six lines of business. The following table presents revenues from these six categories and other revenues for the three and six months ended June 30, 2017 and 2016, respectively: For the Three Months Ended For the Six Months Ended 2017 2016 2017 2016 (In Thousands) Revenues: Spine $ 19,419 $ 17,645 $ 39,757 $ 34,739 Sports medicine and orthopedics 12,997 12,562 25,893 25,082 Surgical specialties 1,456 802 3,236 1,817 Cardiothoracic 3,673 2,905 6,824 5,439 International 6,005 5,663 11,662 11,180 Subtotal direct 43,550 39,577 87,372 78,257 Global commercial 25,837 24,769 49,418 50,099 Other revenues 2,733 3,274 5,269 6,615 Total revenues $ 72,120 $ 67,620 $ 142,059 $ 134,971 Domestic revenues 65,528 61,049 128,835 122,233 International revenues 6,592 6,571 13,224 12,738 Total revenues $ 72,120 $ 67,620 $ 142,059 $ 134,971 The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution: For the Three Months Ended For the Six Months Ended 2017 2016 2017 2016 Percent of revenues derived from: Distributor Zimmer Biomet Holdings, Inc. 14 % 14 % 15 % 15 % Medtronic, PLC 8 % 7 % 9 % 10 % International 9 % 10 % 9 % 9 % The following table presents property, plant and equipment - net by significant geographic location: June 30, December 31, Property, plant and equipment—net: Domestic $ 78,256 $ 77,596 International 6,123 5,702 Total $ 84,379 $ 83,298

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events The Company evaluated subsequent events as of the issuance date of the condensed consolidated financial statements as defined by FASB ASC 855 Subsequent Events, and identified no subsequent events that require adjustment to, or disclosure of, in these condensed consolidated financial statements, except for on August 3, 2017: 1. The Company completed the sale of substantially all of the assets related to its Cardiothoracic closure business (the “CT Business”) to A&E Advanced Closure Systems, LLC (a subsidiary of A&E Medical Corporation) (“A&E”). The sale was completed pursuant to an Asset Purchase Agreement between the Company and A&E, dated August 3, 2017 (the “Asset Purchase Agreement”). As a part of the transaction, the Company also entered into a multi-year Contract Manufacturing Agreement with A&E (the “Contract Manufacturing Agreement”). Under the Contract Manufacturing Agreement, the Company agreed to continue to support the CT Business by manufacturing existing products and engineering, developing, and manufacturing potential future products for A&E. The total consideration received by the Company under the Asset Purchase Agreement was composed of $54,000 in cash consideration, $3,000 of which is being held in escrow for up to twelve months to satisfy possible indemnification obligations, if any, plus an additional $6,000 in contingent cash consideration (the “Contingent Consideration”). Payment of the Contingent Consideration is subject to two conditions: (1) if the Company obtains certain FDA regulatory clearance, then it will be paid $1,000 of the Contingent Consideration; and (2) if A&E reaches certain revenue milestones, then the Company will be paid $5,000 of the Contingent Consideration. 2. Concurrent with the divestiture, the Company entered into a Third Amended and Restated Loan Agreement, dated as of August 3, 2017 (the “2017 Loan Agreement”), among the Company, TD Bank, N.A. and First Tennessee Bank National Association, as Lenders (together with the various financial institutions as in the future may become parties thereto, the “Lenders”), and TD Bank, N.A., as administrative agent for the Lenders. The 2017 Loan Agreement represents a restructuring of the Company’s former loan agreement with TD Bank, N.A. and another lender under the Second Amended and Restated Loan Agreement dated July 16, 2013 between the Company, TD Bank, N.A. and Regions Bank (as amended, the “2013 Loan Agreement”). The 2017 Loan Agreement provides for a revolving credit facility (the “Revolving Credit Facility”), in the aggregate principal amount of $42,500. A total of $35,000 currently is outstanding on the Revolving Credit Facility. The 2017 Loan Agreement also contains a term loan facility in the aggregate principal amount of $25,375 (the “Term Loan Facility” and, together with the Revolving Credit Facility the “Facility”). The Company used $22,000 of the proceeds from the sale of the CT Business to partially pay down amounts owed under the 2013 Loan Agreement. The Facility is secured by substantially all the assets of the Company and its domestic subsidiaries and is guaranteed by the Company’s domestic subsidiaries, as well as 65% of the stock of the Company’s foreign subsidiaries. Borrowings made under the 2017 Loan Agreement initially will bear interest at a rate per annum equal to monthly LIBOR plus a margin of up to 3.50%. Interest is payable quarterly in arrears, and principal on the Term Loan Facility is payable in quarterly payments of $1,125, each commencing October 1, 2017. The maturity date of the Facility is September 15, 2019. The Company may make optional prepayments on the Facility without penalty at the end of any LIBOR interest period.

Recently Issued Accounting St25

Recently Issued Accounting Standards (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Compensation - Stock Compensation	Compensation—Stock Compensation 2017-09, “Compensation—Stock Compensation” Compensation – Stock Compensation No. 2016-09, “Compensation – Stock Compensation” 2016-09”). 2016-09 2016-09 ASU 2016-09 pre-adoption share-based based-payments In addition, under ASU 2016-09 2016-09
Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets	Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets 2017-05, “Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets” 610-20):
Simplifying the Test for Goodwill Impairment	Simplifying the Test for Goodwill Impairment No. 2017-04, Simplifying the Test for Goodwill Impairment” No. 2017-04”). No. 2017-04 No. 2017-04, No. 2017-04 No. 2017-04
Simplifying the Measurement of Inventory	Simplifying the Measurement of Inventory No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” No. 2015-11 first-in, first-out No. 2015-11 No. 2015-11 2015-11 2015-11
Revenue from Contracts with Customers	Revenue from Contracts with Customers No. 2014-09, “Revenue from Contracts with Customers” 2014-09”), “Revenue Recognition” 2014-09 2014-09 2014-09 In March and April 2016, the FASB issued two updates to the revenue recognition guidance: ASU 2016-08 “Principal Versus Agent Considerations” 2016-10, “Identifying Performance Obligations and Licensing” In May 2016, the FASB issued ASU Update No. 2016-12 2016-12”) The Company has not determined the impact ASU 2014-09, 2016-08, 2016-10 2016-12

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options Outstanding, Exercisable and Available for Grant	Stock options outstanding, exercisable and available for grant at June 30, 2017, are summarized as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Life (Years) Value Outstanding at January 1, 2017 5,764,607 $ 4.28 Granted 456,038 4.53 Exercised (426,639 ) 3.69 Forfeited or expired (647,661 ) 5.98 Outstanding at June 30, 2017 5,146,345 $ 4.13 5.63 $ 9,383 Vested or expected to vest at June 30, 2017 4,891,474 $ 4.12 5.47 $ 8,992 Exercisable at June 30, 2017 3,771,493 $ 4.07 4.63 $ 7,235 Available for grant at June 30, 2017 5,281,115
Other Information Concerning Stock Options	Other information concerning stock options are as follows: For the Six Months Ended June 30, 2017 2016 Weighted average fair value of stock options granted $ 2.24 $ 1.55 Aggregate intrinsic value of stock options exercised 533 6
Stock-Based Compensation Recognized	For the three and six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation as follows: For the Three Months Ended For the Six Months Ended June 30, June 30, 2017 2016 2017 2016 Stock-based compensation: Costs of processing and distribution $ 22 $ 33 $ 45 $ 66 Marketing, general and administrative 942 552 1,744 1,004 Research and development 10 15 19 30 Total $ 974 $ 600 $ 1,808 $ 1,100

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Reconciliation of Common Stock used in Calculation of Basic and Diluted Earnings Per Share	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net income per common share is presented below: For the Three Months Ended For the Six Months Ended 2017 2016 2017 2016 Basic shares 58,935,786 58,215,477 58,715,791 58,065,185 Effect of dilutive securities: Stock options — — — — Diluted shares 58,935,786 58,215,477 58,715,791 58,065,185

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Components of Inventories	Inventories by stage of completion are as follows: June 30, December 31, Unprocessed tissue, raw materials and supplies $ 24,959 $ 31,745 Tissue and work in process 42,420 38,552 Implantable tissue and finished goods 49,394 49,446 $ 116,773 $ 119,743

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Components of Property, Plant and Equipment	Property, plant and equipment are as follows: June 30, December 31, Land $ 2,378 $ 2,324 Buildings and improvements 57,092 59,187 Processing equipment 41,843 38,387 Surgical instruments 21,573 18,394 Office equipment, furniture and fixtures 1,704 1,701 Computer equipment and software 18,931 11,852 Construction in process 11,124 17,554 154,645 149,399 Less accumulated depreciation (70,266 ) (66,101 ) $ 84,379 $ 83,298

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Other Intangible Assets	Other intangible assets are as follows: June 30, 2017 December 31, 2016 Gross Accumulated Gross Accumulated Patents $ 11,727 $ 4,565 $ 11,559 $ 4,159 Acquired licensing rights 13,685 8,646 12,204 8,302 Marketing and procurement intangible assets 20,837 9,043 20,694 8,002 Total $ 46,249 $ 22,254 $ 44,457 $ 20,463
Estimates of Future Amortization Expense	At June 30, 2017, management’s estimates of future amortization expense for the next five years are as follows: Amortization 2017 $ 1,700 2018 3,400 2019 3,400 2020 3,400 2021 3,400 2022 3,300 $ 18,600

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
Other Liabilities Disclosure [Abstract]
Accrued Expenses	Accrued expenses are as follows: June 30, December 31, Accrued compensation $ 4,271 $ 4,904 Accrued severance charges 4,494 410 Accrued restructuring charges — 95 Accrued CEO retirement and transition costs 1,096 2,406 Accrued distributor commissions 4,366 4,422 Accrued donor recovery fees 3,376 6,350 Other 3,347 3,443 $ 20,950 $ 22,030

Short and Long-Term Obligatio32

Short and Long-Term Obligations (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Short and Long-Term Obligations	Short and long-term obligations are as follows: June 30, December 31, Term loan $ 47,139 $ 50,347 Credit facility 33,000 33,000 Total 80,139 83,347 Less current portion (5,779 ) (6,080 ) Long-term portion $ 74,360 $ 77,267
Contractual Maturities of Long-Term Obligations	As of June 30, 2017, contractual maturities of long-term obligations are as follows: Term Loan Credit Facility Total 2017 $ 2,873 $ — $ 2,873 2018 44,266 33,000 77,266 $ 47,139 $ 33,000 $ 80,139

Preferred Stock (Tables)

Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Schedule of Preferred Stock	Preferred stock is as follows: Preferred Stock Preferred Stock Net Total Balance at January 1, 2017 $ 60,676 $ (660 ) $ 60,016 Accrued dividend payable 1,834 — 1,834 Amortization of preferred stock issuance costs — 91 91 Balance at June 30, 2017 $ 62,510 $ (569 ) $ 61,941

CEO Retirement and Transition34

CEO Retirement and Transition Costs (Tables)	6 Months Ended
	Jun. 30, 2017
Employee Severance [Member]
Schedule of Restructuring Charges	The following table includes a rollforward of severance charges included in accrued expenses, see Note 9. Accrued severance charges at January 1, 2017 $ 410 Employee separation expenses accrued in 2017 7,803 Subtotal severance charges 8,213 Severance cash payments (3,386 ) Stock based compensation (333 ) Accrued severance charges at June 30, 2017 $ 4,494
Former Chief Executive Officer [Member]
Schedule of Restructuring Charges	The following table includes a rollforward of CEO retirement and transition costs included in accrued expenses, see Note 9. Accrued CEO retirement and transition costs at January 1, 2017 $ 2,406 Cash payments (727 ) Other long-term liabilities portion (583 ) Accrued restructuring charges at June 30, 2017 $ 1,096

Segment Data (Tables)

Segment Data (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Revenues from Tissue Distribution and Other Revenues	The following table presents revenues from these six categories and other revenues for the three and six months ended June 30, 2017 and 2016, respectively: For the Three Months Ended For the Six Months Ended 2017 2016 2017 2016 (In Thousands) Revenues: Spine $ 19,419 $ 17,645 $ 39,757 $ 34,739 Sports medicine and orthopedics 12,997 12,562 25,893 25,082 Surgical specialties 1,456 802 3,236 1,817 Cardiothoracic 3,673 2,905 6,824 5,439 International 6,005 5,663 11,662 11,180 Subtotal direct 43,550 39,577 87,372 78,257 Global commercial 25,837 24,769 49,418 50,099 Other revenues 2,733 3,274 5,269 6,615 Total revenues $ 72,120 $ 67,620 $ 142,059 $ 134,971 Domestic revenues 65,528 61,049 128,835 122,233 International revenues 6,592 6,571 13,224 12,738 Total revenues $ 72,120 $ 67,620 $ 142,059 $ 134,971
Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution: For the Three Months Ended For the Six Months Ended 2017 2016 2017 2016 Percent of revenues derived from: Distributor Zimmer Biomet Holdings, Inc. 14 % 14 % 15 % 15 % Medtronic, PLC 8 % 7 % 9 % 10 % International 9 % 10 % 9 % 9 %
Schedule of Property, Plant and Equipment - Net by Significant Geographic Location	The following table presents property, plant and equipment - net by significant geographic location: June 30, December 31, Property, plant and equipment—net: Domestic $ 78,256 $ 77,596 International 6,123 5,702 Total $ 84,379 $ 83,298

Operations and Organization - A

Operations and Organization - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017FacilityStateCountry
Operations And Organization [Line Items]
Number of states that receive distribution | State	50
Number of countries that receive distribution | Country	45
Alachua, Florida [Member]
Operations And Organization [Line Items]
Number of operating facilities	2
Neunkirchen, Germany [Member]
Operations And Organization [Line Items]
Number of operating facilities	1

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	Jan. 26, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of stock options granted				10 years
Percentage of market value of common stock, stock options exercise price				100.00%
Percentage of market value of common stock, restricted stock award granted				100.00%
Total unrecognized stock-based compensation		$ 1,876,000		$ 1,876,000
Number of options granted				456,038
Exercise price for stock option issued				$ 4.53
Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted				1,950,000
Exercise price for stock option issued				$ 3.20
Stock option expiration date				Jan. 26, 2022
Vesting term				The Stock Options will vest based on the Company’s attainment of three average stock price benchmarks. The first 650,000 shares will vest if the Company’s average publicly traded stock price is over $6.00 for a sixty-consecutive calendar day period. The next 650,000 shares will vest if the Company’s average publicly traded stock price is over $7.00 for a sixty-consecutive calendar day period. The final 650,000 shares will vest if the Company’s average publicly traded stock price is over $8.00 for a sixty-consecutive calendar day period. The vesting of the Stock Options is cumulative.
Former Chief Executive Officer [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted				650,000
Exercise price for stock option issued				$ 6
Former Chief Executive Officer [Member] | Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted				650,000
Exercise price for stock option issued				$ 7
Former Chief Executive Officer [Member] | Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted				650,000
Exercise price for stock option issued				$ 8
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock allowed to be issued		4,656,587		4,656,587
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized stock-based compensation		$ 2,140,000		$ 2,140,000
Stock-based compensation awards, weighted-average period recognized				3 years 4 months 20 days
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period				1 year
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period				5 years
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period			1 year	1 year
Stock-based compensation awards, weighted-average period recognized				1 year 6 months 7 days
Number of shares granted			6,331	148,356
Weighted-average grant date fair value of restricted stock granted			$ 3.70	$ 4.55
Restricted Stock Awards [Member] | Restricted Stock Agreement One [Member] | Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period				4 years
Number of shares granted				850,000
Restricted Stock Awards [Member] | Restricted Stock Agreement One [Member] | Former Chief Executive Officer [Member] | Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest	170,000
Quarterly vesting rate	42,500
Restricted Stock Awards [Member] | Restricted Stock Agreement Two [Member] | Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted		150,000
Number of shares expected to vest		150,000		150,000
Fair value of shares granted		$ 500,000,000		$ 500,000,000
Fair value of shares issued				$ 572,313,000
Shares non transferable period				1 year
Restricted stock award vested effective date				May 18, 2017
Restricted Stock Awards [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period				1 year
Restricted Stock Awards [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period				3 years
Time Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period			3 years	3 years
Number of shares granted			62,500	218,000
Weighted-average grant date fair value of restricted stock granted			$ 3.15	$ 4.60

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options Outstanding, Exercisable and Available for Grant (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding, Number of Shares	5,764,607
Granted, Number of Shares	456,038
Exercised, Number of Shares	(426,639)
Forfeited or expired, Number of Shares	(647,661)
Outstanding, Number of Shares	5,146,345
Vested or expected to vest, Number of Shares	4,891,474
Exercisable, Number of Shares	3,771,493
Available for grant, Number of Shares	5,281,115
Outstanding, Weighted Average Exercise Price | $ / shares	$ 4.28
Granted, Weighted Average Exercise Price | $ / shares	4.53
Exercised, Weighted Average Exercise Price | $ / shares	3.69
Forfeited or expired, Weighted Average Exercise Price | $ / shares	5.98
Outstanding, Weighted Average Exercise Price | $ / shares	4.13
Vested or expected to vest, Weighted Average Exercise Price | $ / shares	4.12
Exercisable, Weighted Average Exercise Price | $ / shares	$ 4.07
Outstanding, Weighted Average Remaining Contractual Life (Years)	5 years 7 months 17 days
Vested or expected to vest, Weighted Average Remaining Contractual Life (Years)	5 years 5 months 20 days
Exercisable, Weighted Average Remaining Contractual Life (Years)	4 years 7 months 17 days
Outstanding, Aggregate Intrinsic Value | $	$ 9,383
Vested or expected to vest, Aggregate Intrinsic Value | $	8,992
Exercisable, Aggregate Intrinsic Value | $	$ 7,235

Stock-Based Compensation - Othe

Stock-Based Compensation - Other Information Concerning Stock Options (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value of stock options granted	$ 2.24	$ 1.55
Aggregate intrinsic value of stock options exercised	$ 533	$ 6

Stock-Based Compensation - St40

Stock-Based Compensation - Stock-Based Compensation Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$ 974	$ 600	$ 1,808	$ 1,100
Costs of Processing and Distribution [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	22	33	45	66
Marketing, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	942	552	1,744	1,004
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$ 10	$ 15	$ 19	$ 30

Net Income Per Common Share - R

Net Income Per Common Share - Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Basic shares	58,935,786	58,215,477	58,715,791	58,065,185
Effect of dilutive securities: Stock options	0	0	0	0
Diluted shares	58,935,786	58,215,477	58,715,791	58,065,185

Net Income Per Common Share - A

Net Income Per Common Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock excluded from the computation of diluted EPS	1,005,138	417,311	687,268	347,038
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock excluded from the computation of diluted EPS	50,000	50,000	50,000	50,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock excluded from the computation of diluted EPS	1,350,051	4,073,600	2,422,661	4,144,433

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Unprocessed tissue, raw materials and supplies	$ 24,959	$ 31,745
Tissue and work in process	42,420	38,552
Implantable tissue and finished goods	49,394	49,446
Inventory - net	$ 116,773	$ 119,743

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Inventory Disclosure [Abstract]
Provision for inventory write-downs	$ 1,964	$ 1,425	$ 3,753	$ 2,370

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 154,645	$ 149,399
Less accumulated depreciation	(70,266)	(66,101)
Property, plant and equipment, net	84,379	83,298
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,378	2,324
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	57,092	59,187
Processing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	41,843	38,387
Surgical Instruments [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	21,573	18,394
Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,704	1,701
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	18,931	11,852
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 11,124	$ 17,554

Property,Plant and Equipment -

Property,Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense in connection with property, plant and equipment	$ 2,652	$ 3,454	$ 5,324	$ 6,836
Assets held for sale	$ 1,750		$ 1,750

Other Intangible Assets - Compo

Other Intangible Assets - Components of Other Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 46,249	$ 44,457
Accumulated Amortization	22,254	20,463
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,727	11,559
Accumulated Amortization	4,565	4,159
Acquired Licensing Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,685	12,204
Accumulated Amortization	8,646	8,302
Marketing and Procurement Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	20,837	20,694
Accumulated Amortization	$ 9,043	$ 8,002

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of other intangible assets	$ 909	$ 930	$ 1,805	$ 1,858

Other Intangible Assets - Estim

Other Intangible Assets - Estimates of Future Amortization Expense (Detail) $ in Thousands	Jun. 30, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 1,700
2,018	3,400
2,019	3,400
2,020	3,400
2,021	3,400
2,022	3,300
Total future amortization expense	$ 18,600

Accrued Expenses - Accrued Expe

Accrued Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued compensation	$ 4,271	$ 4,904
Accrued severance charges	4,494	410
Accrued restructuring charges		95
Accrued CEO retirement and transition costs	1,096	2,406
Accrued distributor commissions	4,366	4,422
Accrued donor recovery fees	3,376	6,350
Other	3,347	3,443
Total accrued expenses	$ 20,950	$ 22,030

Short and Long-Term Obligatio51

Short and Long-Term Obligations - Short and Long-Term Obligations (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Term loan	$ 47,139	$ 50,347
Credit facility	33,000	33,000
Debt and capital lease obligation, total	80,139	83,347
Debt and capital lease obligation, total	80,139	83,347
Less current portion	(5,779)	(6,080)
Long-term portion	$ 74,360	$ 77,267

Short and Long-Term Obligatio52

Short and Long-Term Obligations - Additional Information (Detail) - USD ($)

Mar. 31, 2017

Nov. 07, 2016

Feb. 28, 2017

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Jul. 02, 2018

Dec. 31, 2016

Nov. 06, 2016

Jun. 29, 2016

Jun. 29, 2015

Line of Credit Facility [Line Items]

Credit outstanding

$ 33,000,000

$ 33,000,000

$ 33,000,000

Leverage to EBITDA Ratio

300.00%

Interest expense associated with the amortization of debt issuance costs

150,000

$ 39,000

262,000

$ 78,000

Minimum [Member]

Line of Credit Facility [Line Items]

Leverage to EBITDA Ratio

250.00%

Maximum [Member]

Line of Credit Facility [Line Items]

Leverage to EBITDA Ratio

325.00%

Credit Facility [Member]

Line of Credit Facility [Line Items]

Credit outstanding

33,000,000

33,000,000

Current borrowing capacity

9,500,000

$ 9,500,000

TD Bank and Regions Bank Senior Secured Facility [Member]

Line of Credit Facility [Line Items]

Term of senior secured credit facility

5 years

Amount of senior secured facility obtained

$ 80,000,000

$ 80,000,000

Maturity date of senior secured credit facility

Jul. 16, 2018

Variable interest rate

3.00%

Description of variable interest rate basis

One month LIBOR rate

Revolving credit facility, variable interest rate

4.05%

4.05%

Aggregate principal payment on term loan

$ 6,000,000

Minimum cash balance required for covenant compliance

$ 10,000,000

Covenant Terms of Credit Facility

The credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, as well as payment of dividends, while requiring a minimum cash balance on hand of $10,000 and certain financial covenant ratios.

TD Bank and Regions Bank Senior Secured Facility [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Variable interest rate

1.00%

TD Bank and Regions Bank Senior Secured Facility [Member] | Maximum [Member]

Line of Credit Facility [Line Items]

Variable interest rate

2.75%

TD Bank and Regions Bank Senior Secured Facility [Member] | Scenario, Forecast [Member]

Line of Credit Facility [Line Items]

Amount of final balloon principal payment

$ 41,375,000

TD Bank and Regions Bank Senior Secured Facility [Member] | Revolving Credit Facility [Member]

Line of Credit Facility [Line Items]

Credit facility, borrowing capacity

$ 42,500,000

$ 20,000,000

$ 20,000,000

$ 45,000,000

$ 45,000,000

$ 30,000,000

TD Bank and Regions Bank Senior Secured Facility [Member] | Term Loan [Member]

Line of Credit Facility [Line Items]

Amount of senior secured facility obtained

$ 60,000,000

$ 60,000,000

Short and Long-Term Obligatio53

Short and Long-Term Obligations - Contractual Maturities of Long-Term Obligations (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2,017	$ 2,873
2,018	77,266
Debt and capital lease obligation, total	80,139	$ 83,347
Term Loan [Member]
Debt Instrument [Line Items]
2,017	2,873
2,018	44,266
Debt and capital lease obligation, total	47,139
Credit Facility [Member]
Debt Instrument [Line Items]
2,018	33,000
Debt and capital lease obligation, total	$ 33,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Deferred tax assets	$ 24,868
Deferred tax assets, valuation allowances	$ 5,899
Primary measure of cumulative losses, number of rolling years	3 years
Utilized percentage of deferred tax assets before expiration	100.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Deferred tax assets, valuation allowances	$ 5,899	$ 4,916

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 16, 2013	Jun. 12, 2013	Jun. 30, 2017	Dec. 31, 2016
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Preferred stock issuance cost			$ 569	$ 660
Private Placement with WSHP [Member] | Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Convertible preferred stock issued		$ 50,000
Preferred stock issuance cost	$ 1,290
Private Placement with WSHP [Member] | Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Preferred stock dividend rate	6.00%

Preferred Stock - Schedule of P

Preferred Stock - Schedule of Preferred Stock (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Temporary Equity [Line Items]
Net Total	$ 61,941	$ 60,016
Accrued dividend payable	1,834
Amortization of preferred stock issuance costs	91
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Net Total	62,510	60,676
Preferred Stock Issuance Costs	(569)	$ (660)
Accrued dividend payable	1,834
Amortization of preferred stock issuance costs	$ 91

Severance Charges - Additional

Severance Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Severance charges related to the termination of former employees	$ 3,400	$ 711	$ 7,803	$ 711

Severance Charges - Schedule of

Severance Charges - Schedule of Restructuring Charges (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring Cost and Reserve [Line Items]
Employee separation expenses accrued	$ 3,400	$ 711	$ 7,803	$ 711
Subtotal severance charges		$ 1,107		$ 1,107
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring charges, beginning balance			410
Employee separation expenses accrued			7,803
Subtotal severance charges			8,213
Severance cash payments			(3,386)
Stock based compensation			(333)
Accrued restructuring charges, ending balance	$ 4,494		$ 4,494

CEO Retirement and Transition59

CEO Retirement and Transition Costs - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Former Chief Executive Officer [Member]
Postemployment Benefits Disclosure [Line Items]
Retirement and transition costs	$ 4,404

CEO Retirement and Transition60

CEO Retirement and Transition Costs - Schedule of Restructuring Charges (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Accrued CEO retirement and transition costs at January 1, 2017	$ 2,406
Other long-term liabilities portion	(841)	$ (256)
Accrued restructuring charges at June 30, 2017	1,096
Former Chief Executive Officer [Member]
Restructuring Cost and Reserve [Line Items]
Accrued CEO retirement and transition costs at January 1, 2017	2,406
Cash payments	(727)
Other long-term liabilities portion	(583)
Accrued restructuring charges at June 30, 2017	$ 1,096

Legal Actions - Additional Info

Legal Actions - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017LitigationClaims
Commitments and Contingencies Disclosure [Abstract]
Outstanding claims | Litigation	0
Claims for which the Company Parties are providing defense and indemnification | Claims	1,250

Segment Data - Additional Infor

Segment Data - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of reportable segments	1
Lines of business	6

Segment Data - Revenues from Ti

Segment Data - Revenues from Tissue Distribution and Other Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Other revenues	$ 2,733	$ 3,274	$ 5,269	$ 6,615
Revenues	72,120	67,620	142,059	134,971
Domestic [Member]
Segment Reporting Information [Line Items]
Revenues	65,528	61,049	128,835	122,233
International [Member]
Segment Reporting Information [Line Items]
Revenues	6,592	6,571	13,224	12,738
Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	43,550	39,577	87,372	78,257
Spine [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	19,419	17,645	39,757	34,739
Sports Medicine and Orthopedics [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	12,997	12,562	25,893	25,082
Surgical Specialties [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	1,456	802	3,236	1,817
Cardiothoracic [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	3,673	2,905	6,824	5,439
International [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	6,005	5,663	11,662	11,180
Global Commercial [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	$ 25,837	$ 24,769	$ 49,418	$ 50,099

Segment Data - Schedule of Perc

Segment Data - Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution (Detail) - Distributors Concentration Risk [Member] - Sales Revenue, Net [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Zimmer Biomet Holdings, Inc. [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	14.00%	14.00%	15.00%	15.00%
Medtronic, PLC [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	8.00%	7.00%	9.00%	10.00%
International Customers [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	9.00%	10.00%	9.00%	9.00%

Segment Data - Schedule of Prop

Segment Data - Schedule of Property, Plant and Equipment - Net by Significant Geographic Location (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment - net	$ 84,379	$ 83,298
Domestic [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment - net	78,256	77,596
International [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment - net	$ 6,123	$ 5,702

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Aug. 03, 2017	Jun. 30, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Credit facility, outstanding		$ 33,000,000	$ 33,000,000
Subsequent Event [Member] | 2017 Loan Agreement [Member]
Subsequent Event [Line Items]
Aggregate principal payment on term loan	$ 1,125,000
Debt instrument, date of first required payment	Oct. 1, 2017
Debt instrument, maturity date	Sep. 15, 2019
Subsequent Event [Member] | 2017 Loan Agreement [Member] | Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Credit facility, borrowing capacity	$ 42,500,000
Credit facility, outstanding	35,000,000
Subsequent Event [Member] | 2017 Loan Agreement [Member] | Term Loan [Member]
Subsequent Event [Line Items]
Aggregate principal amount	$ 25,375,000
Subsequent Event [Member] | 2017 Loan Agreement [Member] | LIBOR [Member]
Subsequent Event [Line Items]
Revolving credit facility, variable interest rate	3.50%
Subsequent Event [Member] | 2013 Loan Agreement [Member]
Subsequent Event [Line Items]
Repayments of secured debt	$ 22,000,000
Percentage of foreign subsidiaries stock held as collateral	65.00%
Subsequent Event [Member] | Cardiothoracic [Member]
Subsequent Event [Line Items]
Proceeds from divestiture of businesses	$ 54,000,000
Escrow deposit	3,000,000
Contingent cash consideration receivable	6,000,000
Subsequent Event [Member] | Cardiothoracic [Member] | if the Company obtains certain FDA regulatory clearance
Subsequent Event [Line Items]
Contingent cash consideration receivable	1,000,000
Subsequent Event [Member] | Cardiothoracic [Member] | if A&E reaches certain revenue milestones
Subsequent Event [Line Items]
Contingent cash consideration receivable	$ 5,000,000